v3.25.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Apr. 30, 2025
Oct. 31, 2024
Current assets:    
Cash and cash equivalents $ 1,910,000 $ 1,271,000
Short-term investments 13,687,000 18,653,000
Receivables 173,000
Prepaid expenses and other current assets 1,169,000 1,265,000
Total current assets 16,766,000 21,362,000
Operating lease right-of-use asset 211,000 229,000
Total assets 16,977,000 21,591,000
Current liabilities:    
Accounts payable 284,000 525,000
Accrued expenses 1,566,000 1,946,000
Operating lease liability 37,000 29,000
Total current liabilities 1,887,000 2,500,000
Operating lease liability, non-current 184,000 203,000
Total liabilities 2,071,000 2,703,000
Commitments and contingencies (Note 10)
Shareholders’ equity:    
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 32,211,092 and 32,196,862 shares issued and outstanding as of April 30, 2025 and October 31, 2024, respectively 322,000 322,000
Additional paid-in capital 262,470,000 260,432,000
Accumulated deficit (246,724,000) (240,750,000)
Treasury stock, 2,000 shares at cost as of October 31, 2024 (6,000)
Total shareholders’ equity 16,068,000 19,998,000
Noncontrolling interest (Note 2) (1,162,000) (1,110,000)
Total equity 14,906,000 18,888,000
Total liabilities and equity 16,977,000 21,591,000
Series A Convertible Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, value

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2025
Apr. 30, 2024
Apr. 30, 2025
Apr. 30, 2024
Income Statement [Abstract]        
Revenue
Operating expenses:        
Research and development expenses (including non-cash stock-based compensation expenses of $417, $520, $814 and $1,009, respectively) 1,322 1,646 2,874 2,995
General and administrative expenses (including non-cash stock-based compensation expenses of $571, $740, $1,229 and $1,511, respectively) 1,681 1,821 3,515 4,081
Total operating expenses 3,003 3,467 6,389 7,076
Loss from operations (3,003) (3,467) (6,389) (7,076)
Interest income 190 287 363 606
Net loss (2,813) (3,180) (6,026) (6,470)
Less: Net loss attributable to noncontrolling interest (23) (41) (52) (76)
Net loss attributable to common shareholders $ (2,790) $ (3,139) $ (5,974) $ (6,394)
Net loss per common share attributable to common shareholders:        
Basic $ (0.09) $ (0.10) $ (0.19) $ (0.20)
Diluted $ (0.09) $ (0.10) $ (0.19) $ (0.20)
Weighted average common shares outstanding:        
Basic 32,202 31,914 32,200 31,677
Diluted 32,202 31,914 32,200 31,677

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Apr. 30, 2025
Apr. 30, 2024
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (6,026) $ (6,470)
Stock option compensation to employees and directors 1,993 2,346
Stock options issued to consultants 50 78
Common stock issued to consultants 96
Amortization of operating lease right-of-use asset 18 25
Amortization of discount on held-to-maturity securities (79)
Change in operating assets and liabilities:    
Receivables 173 52
Prepaid expenses and other current assets 96 485
Accounts payable (241) 9
Accrued expenses (380) (360)
Operating lease liability (11) (26)
Net cash used in operating activities (4,407) (3,765)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (24,929) (34,738)
Proceeds from maturities of short-term investments 29,974 35,423
Net cash provided by investing activities 5,045 685
Cash flows from financing activities:    
(Expenses) proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $51 and $94, respectively (3) 3,029
Proceeds from sale of common stock pursuant to an employee stock purchase plan 4 7
Proceeds from exercise of stock options 124
Net cash provided by financing activities 1 3,160
Net increase in cash and cash equivalents 639 80
Cash and cash equivalents at beginning of period 1,271 915
Cash and cash equivalents at end of period $ 1,910 $ 995

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL